| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Colon cancer cell proliferation is significantly inhibited by colonnadin (CBN). At moderate concentrations (up to 25 μM), colondinadin produces apoptosis; at high concentrations (50 μM), it induces necroptosis. The regulation of caspase-9, caspase-3, Bax, Bcl-2, Bim, and Bid is linked to the induction of apoptosis by Columbianadin, while RIP-3 and caspase-8 are linked to the generation of necroptosis. Furthermore, columbanadin causes an imbalance in internal antioxidant enzymes as catalase, GPx-1, SOD-1, and SOD-2 as well as the buildup of ROS. The most effective growth inhibitory action on human colorectal cancer cells was demonstrated by colonidin. Consequently, in order to provide a comprehensive mechanism of Columbianadin-mediated growth inhibition, additional research was carried out employing HCT116 cells. Following 48 and 72 hours of incubation, respectively, cells treated with varying doses of Columbianadin (0-100 μM) displayed dose- and time-dependent growth inhibition, with IC50 values of 47.2 and 32.4 μM. Following a 48-hour treatment with Columbianadin at varying doses (12.5, 25 and 50 μM), HCT116 cells showed a reduction in the number of cells and an increase in floating cells. Round and dead cells showed noticeable morphological alterations when exposed to 25 and 50 μM Columbianadin [1].
|
|---|---|
| ln Vivo |
The tissue distribution of intravenous given Columbianadin (CBN) and Columbianetin (CBT) in rats was effectively studied using this analytical approach. The study's findings demonstrate that, following an intravenous injection, colondanadin can be found in all of the tissues that were chosen. Columbianadin is quickly absorbed by rat tissues, and in the majority of those tissues, it can be converted to CBT via metabolism. The heart had the largest absorption of Columbianadin among the tissues tested, indicating that it could be one of Columbianadin's primary target tissues [2].
|
| References | |
| Additional Infomation |
Columbianadin is an alpha,beta-unsaturated carboxylic ester obtained by formal condensation of the carboxy group of angelic acid with the hydroxy group of 2-[(8S)-2-oxo-8,9-dihydro-2H-furo[2,3-h][1]benzopyran-8-yl]propan-2-ol. It has a role as an anti-inflammatory agent, an apoptosis inducer, a hepatoprotective agent, an antineoplastic agent, a rat metabolite and a plant metabolite. It is a furanocoumarin and an alpha,beta-unsaturated carboxylic ester. It is functionally related to an angelic acid.
Columbianadin has been reported in Semenovia dasycarpa, Cnidium monnieri, and other organisms with data available. |
| Molecular Formula |
C19H20O5
|
|---|---|
| Molecular Weight |
328.364
|
| Exact Mass |
328.131
|
| CAS # |
5058-13-9
|
| PubChem CID |
6436246
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
482.3±45.0 °C at 760 mmHg
|
| Melting Point |
166ºC
|
| Flash Point |
212.7±28.8 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.569
|
| LogP |
3.95
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
589
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C/C=C(/C)\C(=O)OC(C)(C)[C@@H]1CC2=C(O1)C=CC3=C2OC(=O)C=C3
|
| InChi Key |
JRIBPWOXWIRQOQ-GHAIFCDISA-N
|
| InChi Code |
InChI=1S/C19H20O5/c1-5-11(2)18(21)24-19(3,4)15-10-13-14(22-15)8-6-12-7-9-16(20)23-17(12)13/h5-9,15H,10H2,1-4H3/b11-5-/t15-/m0/s1
|
| Chemical Name |
2-[(8S)-2-oxo-8,9-dihydrofuro[2,3-h]chromen-8-yl]propan-2-yl (Z)-2-methylbut-2-enoate
|
| Synonyms |
CBN; Columbianadin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~76.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (10.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0454 mL | 15.2272 mL | 30.4544 mL | |
| 5 mM | 0.6091 mL | 3.0454 mL | 6.0909 mL | |
| 10 mM | 0.3045 mL | 1.5227 mL | 3.0454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
